From triggers to treatment: An epidemiological exploration of anaphylaxis in a lower middle-income area in Colombia
Main Article Content
Keywords
Anaphylaxis, characterization, adults, pediatrics, allergen, adrenaline
Abstract
In this cross-sectional, descriptive, and observational study conducted at Fundación Valle del Lili in Colombia, the clinical and sociodemographic characteristics of anaphylaxis were investigated in a cohort of 80 patients who sought medical care between January 2021 and December 2022. With a median age of 16 years and a notable prevalence among individuals aged below 18 years, the study revealed that 63.8% of patients had concomitant allergic diseases. Medications emerged as the primary triggers for anaphylaxis, followed by food. The mucocutaneous system was predominantly affected in 55% of cases, with respiratory involvement observed in 37.5%. Alarmingly, anaphylactic shock occurred in 17.5%, and 7.5% experienced biphasic anaphylaxis. Intramuscular adrenaline was administered in 88.8% of cases, with 75% of patients not receiving an allergy consultation upon discharge, and 52.5% lacking follow-up for allergy care. Considering that in Colombia epidemiological data on the clinical and sociodemographic aspects of anaphylaxis remain largely unknown, this study documents the features of anaphylaxis in both adult and pediatric populations and highlights the urgent need for improved awareness, timely evaluation by allergists, and comprehensive follow-up care for individuals experiencing anaphylaxis.
References
2. Cardona V, Cabañes N, Chivato T, De La Hoz B, Fernández M, et al. Guía de actuación en ANAFILAXIA: GALAXIA 2016. Sociedad Española de Alergología e Inmunología Clínica (SEAIC) 2016; 19130(2016):1–18.
3. Cardona V, Álvarez-Perea A, Ansotegui-Zubeldia I, Arias-Cruz A, Ivancevich J, González-Díaz S, et al. Guía de Actuación en Anafilaxia en Latinoamérica. Galaxia-Latam. Rev Alerg Mex. 2019; 66(6):1–39. 10.29262/ram.v66i6.588
4. Poowuttikul P, Seth D. Anaphylaxis in Children and Adolescents. Pediatr Clin North Am. 2019;10(01):995–1005. 10.1016/j.pcl.2019.06.005
5. Tanno L, Bierrenbach AL, Simons F, Cardona V, Thong BYH, Molinari N, et al. Critical view of anaphylaxis epidemiology: Open questions and new perspectives. AACI. 2018; 14(1):2. 10.1186/s13223-018-0234-0
6. Cardona V, Chivato T, Diéguez M, Escudero C, Fernández Menéndez V, Fernández Rivas M, et al. Guía de actuación en anafilaxia: GALAXIA 2022. Sociedad Española de Alergología e Inmunología Clínica (SEAIC). 2022; 33(6):474–487. 10.18176/19264-19-0
7. McLendon K, Sternard BT. Anaphylaxis. StatPearls (content is king). Last update: 2023 January 26.
8. Londoño J, Raigosa M, Vásquez M, Sánchez J. Anaphylaxis: State of the art. Iatreia. 2018;31(2):166–79. 10.17533/udea.iatreia.v31n2a05
9. Jares EJ, Cardona V, Gómez RM, Bernstein JA, Rosario Filho NA, Cherrez-Ojeda I, et al. Latin American anaphylaxis registry. World Allergy Organ J. 2023; 16(2):100748. 10.1016/j.waojou.2023.100748
10. de Silva D, Singh C, Muraro A, Worm M, Alviani C, Cardona V, DunnGlvin A, et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy: European Journal of Allergy and Clinical Immunology. 2021;76(5):1493–506. 10.1111/all.14580
11. Long B, Gottlieb M. Emergency medicine updates: Anaphylaxis. Am J Emerg Med. 2021; 49:35–9. 10.1016/j.ajem.2021.05.006
12. Uppala R, Phungoen P, Mairiang D, Chaiyarit J, Techasatian L. Pediatric anaphylaxis: Etiology and predictive factors in an emergency setting. Glob Pediatric Health. 2021; 8:2333794X2110113. 10.1177/2333794X211011301
13. Ikegawa K, Morikawa E, Nigo A, Hataya H, Akasawa A. Epidemiology of anaphylaxis and biphasic reaction in Japanese children. Acute Med Surg. 2021; 8(1):e688. 10.1002/ams2.688
14. Liyanage CK, Galappatthy P, Seneviratne SL. Corticosteroids in management of anaphylaxis; a systematic review of evidence. Eur Ann Allergy Clin Immunol. 2017; 49(05):196. 10.23822/EurAnnACI.1764-1489
15. Dibrin TE, Wasserman S, Turner PJ. Who needs Epineprhine? Anaphylaxis autoinjectors and parachutes. J Allergy Clin Immunol Pract. 2023; 11(4):1036–46. 10.1016/j.jaip.2023.02.002